Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report - Takeaways - MDSpire

Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report

  • By

  • Fang Yang

  • Linli Xuan

  • Jun Li

  • May 25, 2026

  • 0 min

Share

  • 1

    Ivonescimab, a PD-1/VEGF bispecific antibody, can cause severe immune-related adverse events, including IL-6–dominant inflammatory responses.

  • 2

    A 72-year-old man with advanced EGFR-mutant lung cancer developed persistent fever and elevated IL-6 after ivonescimab treatment.

  • 3

    Corticosteroids provided rapid relief from fever, indicating an IL-6–mediated inflammatory process following ivonescimab exposure.

  • 4

    The patient experienced probable arginine vasopressin deficiency, potentially linked to hypophysitis or pituitary metastasis.

  • 5

    Early recognition of steroid-responsive fever and IL-6 monitoring are critical in managing severe immune-mediated reactions.

Original Source(s)

Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report

  • by Fang Yang, Linli Xuan, Jun Li

  • May 25, 2026

Related Content

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Real-world healthcare resource use and costs associated with the management of locally advanced head and neck cancer in Portugal – TRACE2 study